An agent-based model of the response to angioplasty and bare-metal stent deployment in an atherosclerotic blood vessel

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Curtin, Antonia E ^a,c   Zhou, Leming ^a,b  

^a PA 15260   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c University of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; METAL;

ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BARE METAL STENT; BLOOD VESSEL DIAMETER; CYTOKINE PRODUCTION; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; PROTEIN BLOOD LEVEL; RESTENOSIS; SIMULATION; TREATMENT RESPONSE; BIOLOGICAL MODEL; COMPUTER SIMULATION; CORONARY BLOOD VESSEL; ENDOTHELIUM CELL; HUMAN; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SMOOTH MUSCLE FIBER; STENT; SURGERY; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ATHEROSCLEROSIS; COMPUTER SIMULATION; CORONARY VESSELS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; METALS; MODELS, CARDIOVASCULAR; MYOCYTES, SMOOTH MUSCLE; REPRODUCIBILITY OF RESULTS; STENTS; TIME FACTORS;

EID: 84899640939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094411     Document Type: Article

References (82)

1. McCance KL, Huether SE (2009) Pathophysiology: The biologic basis for disease in adults and children. Maryland Heights, MO: Mosby. 1864 p.
2. Fitridge R, Thompson M (2007) Mechanisms of vascular disease: A textbook for vascular surgeons. Cambridge, UK: Cambridge University Press. 173-210.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2014) Heart disease and stroke statistics-2014 update: a report from the american heart association. Circulation 129: e28-e292.
4. Stedman (2006) Stedman's Medical Dictionary. Philadelphia: Lippincott Wiliams & Wilkins.
5. Schillinger M, Minar E (2005) Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag 1: 73-78.
6. Wasser K, Schnaudigel S, Wohlfahrt J, Psychogios MN, Knauth M, et al. (2011) Inflammation and in-stent restenosis: the role of serum markers and stent characteristics in carotid artery stenting. PLoS ONE 6: e22683.
7. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, et al. (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151: 1260-1264. (Pubitemid 43866610)
8. Muller DW, Ellis SG, Topol EJ (1992) Experimental models of coronary artery restenosis. J Am Coll Cardiol 19: 418-432.
9. Touchard AG, Schwartz RS (2006) Preclinical restenosis models: challenges and successes. Toxicol Pathol 34: 11-18.
10. Niazi M, Hussain M (2011) Agent-based computing from multi-agent systems to agent-based models: A visual survey. Springer Scientometrics 89: 479-499.
11. Wilensky U (1999) NetLogo. Center for Connected Learning and Computer-Based Modeling: Northwestern University, Evanston, IL.
12. Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117: 1162-1172. (Pubitemid 30228378)
13. Dinarello CA (2000) Proinflammatory cytokines. Chest 118: 503-508. (Pubitemid 30637822)
14. Thim T, Hagensen MK, Bentzon JF, Falk E (2008) From vulnerable plaque to atherothrombosis. J Intern Med 263: 506-516. (Pubitemid 351545740)
15. Meadows TA, Bhatt DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100: 1261-1275. (Pubitemid 46742917)
16. Waxman S, Freilich MI, Suter MJ, Shishkov M, Bilazarian S, et al. (2010) A case of lipid core plaque progression and rupture at the edge of a coronary stent: elucidating the mechanisms of drug-eluting stent failure. Circ Cardiovasc Interv 3: 193-196.
17. Kovanen PT, Mayranpaa M, Lindstedt KA (2005) Drug therapies to prevent coronary plaque rupture and erosion: present and future. Handb Exp Pharmacol: 745-776.
18. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C (2011) Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des 17: 4190-4209.
19. Charo IF, Taub R (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 10: 365-376.
20. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, et al. (1992) Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20: 467-474.
21. Rodero MP, Khosrotehrani K (2010) Skin wound healing modulation by macrophages. Int J Clin Exp Pathol 3: 643-653.
22. Kondo T, Ishida Y (2010) Molecular pathology of wound healing. Forensic Sci Int 203: 93-98.
23. Virmani R, Farb A (1999) Pathology of in-stent restenosis. Curr Opin Lipidol 10: 499-506. (Pubitemid 30064019)
24. Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378-3384. (Pubitemid 43121822)
25. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA (1991) Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 88: 904-910.
26. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964. (Pubitemid 41746764)
27. Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20: 86-100.
28. Ashcroft GS (1999) Bidirectional regulation of macrophage function by TGFbeta. Microbes Infect 1: 1275-1282. (Pubitemid 30020322)
29. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G (2012) Plateletleukocyte interactions in thrombosis. Thromb Res 129: 263-266.
30. Seye CI, Kong Q, Yu N, Gonzalez FA, Erb L, et al. (2007) P2 receptors in atherosclerosis and postangioplasty restenosis. Purinergic Signal 3: 153-162.
31. Stahl AL, Sartz L, Nelsson A, Bekassy ZD, Karpman D (2009) Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS ONE 4: e6990.
32. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 5: e8668.
33. Berndt MC (2000) Platelets, thrombosis and the vessel wall. Amsterdam: Harwood Academic Publishers.
34. Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, et al. (2005) Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 19: 1998-2004. (Pubitemid 41759745)
35. Groschel K, Riecker A, Schulz JB, Ernemann U, Kastrup A (2005) Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke 36: 367-373. (Pubitemid 40170824)
36. Suwanabol PA, Kent KC, Liu B (2011) TGF-beta and restenosis revisited: a Smad link. J Surg Res 167: 287-297.
37. Rangamani P, Sirovich L (2007) Survival and apoptotic pathways initiated by TNF-alpha: modeling and predictions. Biotechnol Bioeng 97: 1216-1229. (Pubitemid 47195318)
38. Grainger DJ (2004) Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24: 399-404. (Pubitemid 38326130)
39. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, et al. (2009) TGFbeta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297: H540-549.
40. Welt FG, Rogers C (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22: 1769-1776. (Pubitemid 35315761)
41. Brown BN, Price IM, Toapanta FR, DeAlmeida DR, Wiley CA, et al. (2011) An agent-based model of inflammation and fibrosis following particulate exposure in the lung. Math Biosci 231: 186-196.
42. Li NY, Verdolini K, Clermont G, Mi Q, Rubinstein EN, et al. (2008) A patientspecific in silico model of inflammation and healing tested in acute vocal fold injury. PLoS ONE 3: e2789.
43. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S (2010) The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med 153: 387-395.
44. Murphy BP, Savage P, McHugh PE, Quinn DF (2003) The stress-strain behavior of coronary stent struts is size dependent. Ann Biomed Eng 31: 686-691.
45. Kolodgie FD, Nakazawa G, Sangiorgi G, Ladich E, Burke AP, et al. (2007) Pathology of atherosclerosis and stenting. Neuroimaging Clin N Am 17: 285-301. (Pubitemid 47362741)
46. Stoeckel D, Bonsignore C, Duda S (2002) A survey of stent designs. Minim Invasive Ther Allied Technol 11: 137-147.
47. Botnar RM, Stuber M, Kissinger KV, Kim WY, Spuentrup E, et al. (2000) Noninvasive coronary vessel wall and plaque imaging with magnetic resonance imaging. Circulation 102: 2582-2587.
48. Blann AD, Wang JM, Wilson PB, Kumar S (1996) Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120: 221-226. (Pubitemid 26053317)
49. Wildgruber M, Weiss W, Berger H, Wolf O, Eckstein HH, et al. (2007) Association of circulating transforming growth factor beta, tumor necrosis factor alpha and basic fibroblast growth factor with restenosis after transluminal angioplasty. Eur J Vasc Endovasc Surg 34: 35-43. (Pubitemid 46852386)
50. Kimura T, Nosaka H, Yokoi H, Iwabuchi M, Nobuyoshi M (1993) Serial angiographic follow-up after Palmaz-Schatz stent implantation: comparison with conventional balloon angioplasty. J Am Coll Cardiol 21: 1557-1563. (Pubitemid 23170426)
51. Hamid H, Coltart J (2007) 'Miracle stents'-a future without restenosis. McGill J Med 10: 105-111. (Pubitemid 351426561)
52. Chamie D, Costa JR Jr, Abizaid A, Feres F, Staico R, et al. (2010) Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). JACC Cardiovasc Interv 3: 191-202.
53. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, et al. (1996) Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94: 1247-1254. (Pubitemid 26307249)
54. Pries AR, Reglin B, Secomb TW (2005) Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli. Hypertension 46: 725-731. (Pubitemid 43186745)
55. Stefanescu RA, Shivakeshavan RG, Talathi SS (2012) Computational models of epilepsy. Seizure 21: 748-759.
56. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, et al. (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331: 496-501. (Pubitemid 24256752)
57. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, et al. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331: 489-495. (Pubitemid 24256751)
58. Mohan S, Dhall A (2010) A comparative study of restenosis rates in bare metal and drug-eluting stents. Int J Angiol 19: e66-72.
59. Costa MA, Simon DI (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111: 2257-2273. (Pubitemid 40632443)
60. Ward MR, Pasterkamp G, Yeung AC, Borst C (2000) Arterial remodeling. Mechanisms and clinical implications. Circulation 102: 1186-1191.
61. Otsuka F, Nakano M, Ladich E, Kolodgie FD, Virmani R (2012) Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. Thrombosis 2012: 608593.
62. Zhang F, Qian J, Dong L, Ge J (2012) Super late stent thrombosis occurred at 8 years after drug-eluting stent implantation. Int J Cardiol 159: e53-55.
63. Auerbach D, Maeda J, Steiner C (2012) Hospital stays with cardiac stents, 2009. Rockville, MD: Agency for Healthcare Research and Quality.
64. King SB (2002) Restenosis following angioplasty. In: Waksman R, editor. Vascular Brachytherapy. 3rd ed. Armonk, NY: Futura Publishing Co., Inc. 3-11.
65. Chitkara K, Pujara K (2010) Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? Eur J Cardiovasc Med 1: 20-24.
66. Homoncik M, Jilma B, Eichelberger B, Panzer S (2000) Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation. Thromb Res 99: 461-466.
67. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
68. Poorhosseini HR, Hosseini SK, Davarpasand T, Lotfi Tokaldany M, Salarifar M, et al. (2012) Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation. J Tehran Heart Cent 7: 47-52.
69. Lee KH, Ahn Y, Kim SS, Rhew SH, Jeong YW, et al. (2013) Comparison of Triple Anti-Platelet Therapy and Dual Anti-Platelet Therapy in Patients With Acute Myocardial Infarction Who Had No-Reflow Phenomenon During Percutaneous Coronary Intervention. Circ J 77: 2973-2981.
70. Friedman H, Mollon P, Lian J, Navaratnam P (2013) Clinical outcomes, health resource use, and cost in patients with early versus late dual or triple anti-platelet treatment for acute coronary syndrome. Am J Cardiovasc Drugs 13: 273-283.
71. Mulukutla SR, Marroquin OC, Vlachos HA, Selzer F, Toma C, et al. (2013) Benefit of long-term dual anti-platelet therapy in patients treated with drugeluting stents: from the NHLBI dynamic registry. Am J Cardiol 111: 486-492.
72. Pappas C, Ntai K, Parissis JT, Anastasiou-Nana M (2013) Dual anti-platelet therapy in patients with G6PD deficiency after percutaneous coronary intervention. Int J Cardiol 165: 380-382.
73. Subban V, Kalidoss L, Sankardas MA (2012) Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy. Cardiovasc J Afr 23: e9-11.
74. Facoetti A, Mariotti L, Ballarini F, Bertolotti A, Nano R, et al. (2009) Experimental and theoretical analysis of cytokine release for the study of radiation-induced bystander effect. Int J Radiat Biol 85: 690-699.
75. DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA (1993) Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol 122: 729-737. (Pubitemid 23226689)
76. Sagnella SM, Kligman F, Anderson EH, King JE, Murugesan G, et al. (2004) Human microvascular endothelial cell growth and migration on biomimetic surfactant polymers. Biomaterials 25: 1249-1259. (Pubitemid 37476202)
77. Heikkila HM, Latti S, Leskinen MJ, Hakala JK, Kovanen PT, et al. (2008) Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 28: 309-314. (Pubitemid 351187646)
78. Najean Y, Ardaillou N, Dresch C (1969) Platelet lifespan. Annu Rev Med 20: 47-62.
79. Noma H, Kato T, Fujita H, Kitagawa M, Yamano T, et al. (2009) Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. Immunology 128: e487-496.
80. Ferkol T, Perales JC, Mularo F, Hanson RW (1996) Receptor-mediated gene transfer into macrophages. Proc Natl Acad Sci USA 93: 101-105. (Pubitemid 26038110)
81. Heidenreich S (1999) Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 65: 737-743. (Pubitemid 29279520)
82. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, et al. (2010) In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116: 625-627.